[ad_1]
The Altria group, manufacturer of the Marlboro brand of cigarettes, announced the conclusion of an agreement for the acquisition of new shares of the group Canadian Cronos, a leading manufacturer. Cannabinoids in the world. The transaction represents a 45% stake at a price of about $ 1.8 billion
. The cigarette giant expects its investment to help the Cronos group accelerate its growth strategies and development in research and intellectual property. These services may include regulatory issues, regulatory science, compliance, government affairs, and brand management.
The leading marijuana badyst on Wall Street viewed advertising as a "unique entry into cannabis." Vivien Azer, an badyst at Cowen, said Vivien Azer, an badyst at Cowen.
"Although the potential uses of cannabinoids are enormous, Cronos will focus on rare cannabinoids." Cronos believes the key to successful cannabinoid-based products is to create reliable, consistent production and evolutionary of a full spectrum of about 100 cannabinoids, not just THC and CBD ", shows an excerpt from the badysis [AccordingtotheAltriaandConospeuvenexploitingoperationalresourcesandtheAsponsideredAltriapourcreateadded-valuefactorsandconcentratingconcentrantsofthedomethodompositionwithoutthin#39supportedbyahugeinfrastructureofagriculture(19659006)MarlboroofMarijuana?
Agreement The agreement includes the possibility of acquiring an additional interest in the Cronos group over a four-year period. If it was fully exercised, the mandate would increase Altria's stake in the Cronos group by about 10%, to reach about 55%. "Investing in the Cronos Group as an exclusive partner in the new marijuana category represents a new growth opportunity for Altria," said Howard Willard, chairman and chief executive officer of Altria. This investment will allow Altria to participate in the new global cannabis sector, which is ready for rapid growth over the next decade. It also creates a new growth opportunity in an adjacent category, complementary to the large tobacco companies of the Altria group. "Altria's investment income will allow us to further expand our global infrastructure and distribution footprint, R & D investments and brands that resonate with our consumers", said Mike Gorenstein, president and CEO of Cronos Group.
[ad_2]
Source link
